Cargando…

Prognostic impact of ATM mutations in patients with metastatic colorectal cancer

Tumors bearing homologous recombination deficiency are extremely sensitive to DNA double strand breaks induced by several chemotherapeutic agents. ATM gene, encoding a protein involved in DNA damage response, is frequently mutated in colorectal cancer (CRC), but its potential role as predictive and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Randon, Giovanni, Fucà, Giovanni, Rossini, Daniele, Raimondi, Alessandra, Pagani, Filippo, Perrone, Federica, Tamborini, Elena, Busico, Adele, Peverelli, Giorgia, Morano, Federica, Niger, Monica, Antista, Maria, Corallo, Salvatore, Saggio, Serena, Borelli, Beatrice, Zucchelli, Gemma, Milione, Massimo, Pruneri, Giancarlo, Di Bartolomeo, Maria, Falcone, Alfredo, de Braud, Filippo, Cremolini, Chiara, Pietrantonio, Filippo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393680/ https://www.ncbi.nlm.nih.gov/pubmed/30814645 http://dx.doi.org/10.1038/s41598-019-39525-3

Ejemplares similares

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
por: Morano, Federica, et al.
Publicado: (2019)

Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective
por: Prisciandaro, Michele, et al.
Publicado: (2022)

Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan
por: Pietrantonio, Filippo, et al.
Publicado: (2020)

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O(6)-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
por: Morano, Federica, et al.
Publicado: (2022)

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
por: Fucà, Giovanni, et al.
Publicado: (2022)

The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2019)

Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2020)

Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
por: Cremolini, Chiara, et al.
Publicado: (2019)

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
por: Pietrantonio, Filippo, et al.
Publicado: (2016)

The Landscape of Actionable Gene Fusions in Colorectal Cancer
por: Pagani, Filippo, et al.
Publicado: (2019)

Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
por: Fucà, Giovanni, et al.
Publicado: (2021)

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study
por: Cremolini, Chiara, et al.
Publicado: (2017)

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials
por: Cremolini, Chiara, et al.
Publicado: (2018)

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials
por: Fucà, Giovanni, et al.
Publicado: (2020)

Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal Cancer
por: Randon, Giovanni, et al.
Publicado: (2023)

MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers
por: Niger, Monica, et al.
Publicado: (2022)

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
por: Oddo, Daniele, et al.
Publicado: (2017)

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis
por: Cremolini, Chiara, et al.
Publicado: (2017)

Author response to Colle et al
por: Fucà, Giovanni, et al.
Publicado: (2021)

Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient
por: Milione, Massimo, et al.
Publicado: (2017)

Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable
por: Ongaro, Elena, et al.
Publicado: (2019)

The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
por: Raimondi, Alessandra, et al.
Publicado: (2019)

Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status
por: Pietrantonio, Filippo, et al.
Publicado: (2014)

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
por: Antoniotti, Carlotta, et al.
Publicado: (2020)

Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model
por: Azzollini, Jacopo, et al.
Publicado: (2022)

Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis
por: Milione, Massimo, et al.
Publicado: (2020)

HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial
por: Pietrantonio, Filippo, et al.
Publicado: (2023)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo, Maria, et al.
Publicado: (2015)

A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer
por: Reduzzi, Carolina, et al.
Publicado: (2019)

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial
por: Di Bartolomeo, Maria, et al.
Publicado: (2019)

Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2023)

Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies
por: Iacovelli, Roberto, et al.
Publicado: (2014)

Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin
por: Zattarin, Emma, et al.
Publicado: (2022)

The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence
por: Pusceddu, Sara, et al.
Publicado: (2020)

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
por: Rossini, Daniele, et al.
Publicado: (2022)

Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase
por: Falvella, Felicia Stefania, et al.
Publicado: (2015)

Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti–EGFR-Based Therapy
por: Randon, Giovanni, et al.
Publicado: (2022)

Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study
por: Fucà, Giovanni, et al.
Publicado: (2019)

Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma
por: Silvestri, Marco, et al.
Publicado: (2023)

One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches
por: Niger, Monica, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ctisnj96fp3oh84hqpp6uffi93